Table of Contents Author Guidelines Submit a Manuscript
Volume 2014 (2014), Article ID 145764, 7 pages
Research Article

Epidemiology, Treatment Patterns, and Outcomes of Metastatic Soft Tissue Sarcoma in a Community-Based Oncology Network

1Department of Information Technology, Health Economics and Outcomes Research, McKesson Specialty Health, The Woodlands, TX, USA
2GlaxoSmithKline, Philadelphia, PA 19112, USA
3Texas Oncology, Dallas, TX, USA
4Baylor Charles A. Sammons Cancer Center, Dallas, TX, USA
5Baylor University Medical Center at Dallas, Dallas, TX, USA
6Texas Oncology, Baylor Sammons Cancer Center, 3410 Worth Street, Dallas, TX 75246, USA

Received 22 August 2013; Revised 13 December 2013; Accepted 15 December 2013; Published 12 January 2014

Academic Editor: Charles Catton

Copyright © 2014 Clara Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Supplementary Material

Supplementary material included online only includes the following figures and tables: Figure 1 depicts the patient consort diagram. Table 1 shows the use of monotherapy versus combination therapy according to histology subtype. Among those receiving combination and monotherapy, 56% and 40%, respectively, had the top 3 subtypes. Table 2 depicts overall survival and progression-free survival. Approximately 40% of treated and untreated patients died during follow-up. Median overall survival of treated patients was 22 months and for untreated patients it was 17 months. Table 3 shows overall survival estimates of patients stratified by STS subtype, and Table 4 and Figure 2 show progression-free survival stratified by the STS subtypes leiomyosarcoma, liposarcoma, synovial sarcoma, and other.

  1. Supplementary Materials